tbuckley/cabot-search huggingface dataset:
A phase II trial of once-weekly hypofractionated breast irradiation (WHBI): Interim analysis of cosmetic outcome and quality of life.
Authors: Anthony E. Dragun, Elizabeth Carloss Riley, Amy R. Quillo, Parul Nafees Barry, Allison M. Hunter, Akanksha A. Rajeurs, Teresa Roberts, Shesh Rai, Jianmin Pan, Dharamvir Jain, Charles Raben Scoggins, Kelly McMasters
Journal: Journal of Clinical Oncology (2014)

67 Background: A planned interim analysis of an institutional Phase II trial of once-weekly radiotherapy for patients undergoing breast-conserving surgery (BCS). Methods: Patients who underwent BCS for AJCC Stage 0, I or II breast cancer with negative surgical margins were eligible to receive whole-breast radiotherapy to a dose of 30Gy in 5 weekly fractions of 6 Gy with or without an additional boost. There were no restrictions on age, breast size or the use of cytotoxic chemotherapy for otherwise eligible patients. Patients were evaluated at baseline, 6 and 12 months with digital photography, physician assessment of cosmesis (Harvard Scale) and self-assessment (BCTOS). Results: Between January 2011 and January 2013, 82 eligible patients underwent WHBI immediately following BCS (82.7%) or at the conclusion of adjuvant cytotoxic chemotherapy (17.3%). The median age was 60 years (range: 30-80y) and the median followup was 33.1 months and all patients had at least 1 year followup. The rate of Excellent/Good vs. Fair/Poor cosmesis at 12 months was 77.3% vs. 22.7%. The rate of significant cosmetic change from baseline was 14.7%. The only factor predictive of significant cosmetic change was smoking status (OR: 6.94; p = 0.016). The median BCTOS score increased only slightly from baseline (31) to one year (32), with patient-reported breast size differences worsening but complaints of pain improving over the study period. Conclusions: Cosmetic outcome after WHBI compares well with reports of daily hypofractionated whole-breast irradiation. Further follow-up with continued accrual is needed to assess cosmetic stability and disease-specific outcomes. Clinical trial information: NCT01278212.
Abstract 15010: Prevalence Distribution and Response to Endocardial Ablation of Abnormal Epicardial Recordings in Patients with Ischemic Cardiomyopathy
Authors: Luigi Di Biase, Pasquale Santangeli, J. David Burkhardt, Rong Bai, Prasant Mohanty, Sanghamitra Mohanty, Agnes Pump, Chintan Trivedi, Rachel Xue Yan, Justin Price, Javier E. Sanchez, G. Joseph Gallinghouse, Salwa Beheiry, Richard Hongo, Shane M. Bailey, Rodney Horton, Jason D. Zagrodzky, Madhu Reddy, Dhanunjay Lakkireddy, Corrado Carbucicchio, Michela Casella, Antonio Dello Russo, Claudio Tondo, Andrea Natale
Journal: Circulation (2012)

Introduction: Endocardial catheter ablation for ventricular arrhythmias (VA) and electrical storm (ES) in patients with ischemic cardiomyopathy has shown moderate long term results. The reported ne...
Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7229
Authors: E. Chuang, L. Vahdat, T. Caputo, G. Goldberg, A. Flam, P. Christos, A. Colevas, F. Muggia, S. Wadler
Journal: Journal of Clinical Oncology (2007)

2570 Background: Ixabepilone (IX) is a semisynthetic epothilone B analog with activity in patients (pts) with taxane refractory cancer. Two phase III clinical trials in breast cancer (BC) and a phase II study in ovarian cancer (OC) have recently been completed. Pegylated liposomal doxorubicin (PLD) is used for the treatment of platinum refractory OC and has activity in patients with metastatic BC. Methods: We have completed enrollment of a phase I study of PLD IV and ixabepilone IV over 3 hours. 18 pts with metastatic cancer (10 BC and 8 OC) with median age 51 were enrolled from 1/13/06 to 12/22/06. A total of 60 cycles has been administered to date. 3 OC patients enrolled at dose level 3 have not yet completed 2 cycles of treatment and are not yet evaluable. Results: Dose limiting toxicities (DLT) based on toxicities experienced during the first 2 cycles is provided in the table below. Adverse events (AE) occurring in any cycle were: Grade 4 AE: neutropenia &lt; 7 days (1 pt). Grade 3 AE: palmar plantar erythrodysesthesia (PPE) (4), mucositis (3), infection (2), fatigue (2), neutropenia (2), thrombocytopenia (2), anemia (1), neuropathy (1), bilirubin (1). Non-hematological grade 2 AEs included: mucositis (4), PPE (3), infection (2), neuropathy (2), rash (3), pain (3), fever (1), myalgias (1), and anorexia (1). Responses so far for 10 BC pts are PR (1) SD (3) PD (6) and for 5 OC pts are PR (1) SD (2) PD (2). Updated results will be presented. Conclusions: Although the recommended phase II dose when given every 3 weeks is 30 mg/m2 for PLD and 32 mg/m2 for IX by our criteria, PPE and mucositis became problematic when treatment was continued beyond 2 cycles. We are therefore exploring a 4 week PLD schedule, evaluating IX given either every 4 weeks (as shown) or weekly (on days 1, 8, and 15). A phase II trial of the combination in platinum refractory OC will be initiated upon completion of the phase I. Supported by N01-CM-62204 [Table: see text] [Table: see text]
Lymphatic vessel density is not associated with lymph node metastasis or survival in non-small cell lung carcinoma (NSCLC)
Authors: V. M. Villaflor, L. Faoro, J. Hutto, J. Varalakshmi, K. Suzue, E. Vokes, A. Husein, R. Salgia
Journal: Journal of Clinical Oncology (2007)

18008 Background: Angiogenesis is accepted as being essential for tumors to grow and metastasize to distant sites. Lymphatic metastasis is also an important means of tumor spread. Vascular endothelial growth factor C (VEGF-C) plays and important role in lymphangiogenesis and activates VEGFR (VEGF receptor)-3. Numerous studies suggest that tumor expression of VEGF-C is a significant prognostic factor in NSCLC. In non-small cell lung carcinoma (NSCLC), the relationship of lymphangiogenesis with lymph node metastasis and patient prognosis is unknown. Methods: A retrospective analysis of 78 patients who were diagnosed with NSCLC from 1987 to 2004 were analyzed for lymphatic vascular density (LVD). LVD was measured by use of D2–40 monoclonal antibody staining. Survival was assessed and Mantel-Cox and Wilcoxon signed rank tests were used for statistical analysis. Results: Intratumoral and peritumoral LVD was significantly higher than in the uninvolved adjacent lung, but showed no significant association with lymph node status at the time of tumor resection. Variables which appeared to affect survival in our study were the presence of lymph node metastasis (median survival 1,425 vs absence 467 days, p=0.002). The presence of VEGF staining inversely affected median survival (present 757 vs absent 1,944 days, p= 0.014). LVD ≤ 53 events per field 895 days vs &gt;53 median survival 1,302 days, p+0.867. Survival appeared to not be affected by LVD. Conclusions: These data suggest that although lymphangiogenesis occurs in association with NSCLC, it may not be an important factor in lymph node metastasis or in survival. In fact, there is a suggestion that the number of lymphatics that a patient inherently has appears to be more important than lymphangiogenesis when it comes to the development of lymph node metastasis. No significant financial relationships to disclose.
Liver resectability following mFOLFOX6 with bevacizumab as the first-line treatment of unresectable liver limited metastases from colorectal cancer in Japanese patients (KSCC 0802).
Authors: Hironori Samura, Toru Beppu, Yasunori Emi, Yoshihiro Kakeji, Hiroshi Saeki, Eiji Oki, Fumihiko Fujita, Masahumi Inomata, Terumitsu Sawai, Yoshito Akagi, Hideo Baba, Shoji Natsugoe, Yutaka Ogata, Shoji Tokunaga, Yoshihiko Maehara
Journal: Journal of Clinical Oncology (2012)

666 Background: There is no data concerning liver resectability following mFOLFOX6 with bevacizumab as the first-line treatment of unresectable liver limited metastases from colorectal cancer by prospective, multi-center study in Japan. The Kyushu Study group of Clinical Cancer (KSCC) conducted a phase II trial in this setting. Methods: Eligibility criteria included unresectable liver limited metastases from histologically confirmed advanced colorectal cancer, ECOG PS 0-1 and adequate general condition. Patients (pts) received 6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m 2 , l-leucovorin 200 mg/m 2 d1 followed by 400 mg/m 2 bolus 5-FU and a 46-hr 2,400 mg/m 2 5-FU infusion every 2 weeks) with bevacizumab (5mg/kg) followed by evaluating the liver resectability. (UMIN000001308) Results: Of the 40 pts enrolled from Sept. 9 2008 to Aug. 10 2010; M/F, 29/11; Median age, 63 years (range 37-74); ECOG PS 0/1, 38/2. The median number of administration cycles was 6 (range, 1–7). Response for CR, PR, SD, PD and NE were 0 (0 %), 12 (30.0 %), 22 (55.0%), 3 (7.5%) and 3 (7.5%), respectively. An overall response rate was 30.0% (95% CI: 16.6 % – 46.5 %). The grade 3-4 adverse events were; leukopenia (10%), neutropenia (32.5%), febrile neutropenia (5%), fatigue (2.5%), appetite loss (2.5%), diarrhea (2.5%), mucositis (2.5%), high AST (2.5%) and ileus (2.5%). The number of cases to intent operation was 17 (42.5%), the liver resectability was 16/40 (40.0 %). The number of R0 cases was 10 pts (25.0%, 95% CI; 12.7 - 41.2 %). Conclusions: mFOLFOX6 with bevacizumab regimen is safe and effective for unresectable liver limited metastases from colorectal cancer, and might be to lead the high liver resectability.
Abstract 12941: Disease Progression in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy and Ventricular Tachycardia: A Longitudinal Study With Unipolar Voltage Mapping
Authors: Pasquale Santangeli, Ioan Liuba, Cory Tschabrunn, Michael Riley, Fermin Garcia, Rupa Bala, Mathew Hutchinson, Gregory Supple, David Lin, David Frankel, Robert Schaller, David Callans, Erica Zado, Francis Marchlinski
Journal: Circulation (2014)

Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is believed to result in progressive fibrofatty replacement of the RV myocardium with development of multiple ventricular tachycardia (VT) circuits. Endocardial unipolar voltage mapping has been shown to reliably identify epicardial and endocardial (epi-endo) scar in ARVC. Hypothesis: We studied the prevalence and mechanisms of disease progression in patients with ARVC and VT through longitudinal unipolar voltage mapping studies. Methods: Eighteen consecutive patients (age 38±14 years) who fulfilled the revised Task Force criteria for ARVC underwent two detailed sinus rhythm endocardial unipolar voltage maps (mean 348±118 points) performed a median of 36 months apart (interquartile range 21 to 36 months, minimum 9 months) as part of VT ablation procedures. Epi-endo scar was defined using established unipolar voltage cutoff (5.5 mV). The extent of RV scar and total RV volume was measured by a dedicated software. A &gt;5% increase in RV scar area or volume over follow-up was considered significant. Results: At baseline, all patients had evidence of epi-endo RV scar (mean 141±82 cm 2 ; 56±27% of the RV surface area). After a mean follow-up of 49±36 months, no significant progression of unipolar voltage scar was observed (mean 159±83 cm 2 , P=0.14; 63±27% of the RV surface area, P=0.07). Specifically, only 3 (17%) patients presented with progression of the RV scar &gt;5%. The RV volumes increased during follow-up (from 206±74 mL to 258±77 mL, P=0.0003), with the majority of patients (15/18, 83%) having a significant increase in the RV volume (mean increase = 38.9%). Only 3 (17%) patients had no change in both RV scar size and volume over time. Conclusions: In patients with ARVC and VT, progressive RV dilatation is almost uniformly observed, while rapid epi-endo scar progression is rare. These findings suggest that aggressive epi-endocardial substrate ablation should provide long-term VT control, and further research is needed to identify the mechanism(s) for and to prevent ongoing RV dilatation in these patients.
Efficacy of selective estrogen receptor modulators (SERMs) in a murine xenograft model bearing human bladder cancer
Authors: G. Sonpavde, J. Yu, C. Smith, S. Shen, H. Weiss, S. P. Lerner
Journal: Journal of Clinical Oncology (2005)

4582 We have demonstrated through Western Blot and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) that estrogen receptor (ER)-beta is expressed in RT-4, 5637, T-24, TSU-PR1 and TCC-SUP human bladder cancer cell lines, while ER-alpha is expressed at very low levels. Raloxifene, a SERM, induced apoptosis and decreased the viability of RT-4, T-24, and 5637 cell-lines in-vitro. Using tissue microarray analysis ER-beta was expressed in 133 (63.3%) of 210 bladder tumors, while ER-alpha was expressed in only 2 tumors. The expression of ER-beta was associated with higher stage and grade. We constructed a murine xenograft model bearing human bladder cancer to evaluate the efficacy of SERMs in an animal model. A total of 107 5637 human transitional cell carcinoma cells (suspended in 0.1 ml of a 1:1 mixture of RPMI with 10% FBS and matrigel) were injected into one site at a mammary fat pad of 6–8 week old female athymic BALB/c nu/nu mice. Only mice that developed measurable subcutaneous tumor (at least 3 mm in one dimension) within 2 weeks were chosen for further study. Raloxifene 100 mg (Sigma-Aldrich) powder was suspended in 9 ml of double-distilled water. One milliliter of 90% CMC and 10% PEG400/Tween80 was added to the raloxifene solution for a final concentration of 10 mg/ml. Five cohorts of mice consisting of 6–8 mice per cohort were administered no therapy, placebo (solvent only without raloxifene), raloxifene 0.01 mg/day, raloxifene 0.1 mg/day and raloxifene 1 mg/day for 5 days a week by oral gavage for 8 weeks. All of the doses of raloxifene significantly inhibited the growth of tumor (p<0.05). In a separate experiment, 107 5637 cells were subcutaneously injected into the flanks of 6–8 week old female athymic nu/nu mice. Four cohorts of mice with measurable tumors with 6–8 mice per cohort were implanted with subcutaneous 60-day time-release pellets (Innovative Research of America, Sarasota, FL) delivering placebo, tamoxifen 0.008 mg/day, tamoxifen 0.125 mg/day and tamoxifen 1.25 mg/day, respectively. Significant inhibition of tumor was observed with all of the doses of tamoxifen (p< 0.01). These data provide the rationale for evaluating SERMs as a targeted therapuetic for patients with bladder cancer. No significant financial relationships to disclose.
Clinical characteristics of mucinous adenocarcinoma of the ovary
Authors: M. Shimada, J. Kigawa, R. Nishimura, M. Suzuki, T. Kita, T. Sugiyama, M. Hiura, T. Kaku, H. Tsuda, N. Terakawa
Journal: Journal of Clinical Oncology (2005)

5061 Background: Platinum-based chemotherapy showed the good response to epithelial ovarian cancer. Recently, it has been reported that histological subtype of epithelial ovarian cancer strongly affects the chemo-sensitivity. Clinical pathological feature of mucinous adenocarcinoma of the ovary (MAC), which occupies about 15% of epithelial ovarian cancer, has been unknown. We conducted the retrospective review to know clinical characteristics of MAC. The present study involved the largest series of patients with MAC. Methods: A total of 926 patients with epithelial ovarian cancer were treated in our institutes between 1998 and 2003. Four hundred thirty five patients (46.8%) with serous adenocarcinoma (SAC) and 134 patients (14.5%) with MAC were examined in the present study. All patients were identified with the medical records. In all pathologic specimens of MAC, histological evaluation was performed under central pathological review. Results: The mean age of patients with MAC was 51.3 years (range: 12–82 years). Out of 134 cases, there were 91 in stage I (45 in stage Ia, 2 in stage Ib, and44 in stage Ic), 10 in stage II, 26 in stage III, and 7 in stage IV. The 3-year survival rate of patients with MAC was 96.7% for stage Ia-b, 94.2% for stage Ic, 62.2% for stage II, 67.2% for stage III, and 57.1% for stage IV. The outcome of patients for stage I was significantly better than that for stage II-IV. The outcome of patients with MAC receiving optimal operation was significantly better than that not receiving optimal operation in patients with stage II-IV (3-year survival; 80.0% vs. 41.7%). The response rate to platinum-based chemotherapy in patients with MAC was significantly lower than that in patients with SAC (Table 1). Conclusions: The response to platinum-based chemotherapy in patients with MAC was significantly worse. Optimal operation might be important for an improvement of the outcome in stage II-IV patients with MAC. No significant financial relationships to disclose.
Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy
Authors: V. R. Peddareddigari, P. W. Miller, B. B. Nebiyou, W. W. Overwijk, M. I. Ross, J. E. Lee, J. E. Gershenwald, V. G. Prieto, P. Hwu, L. Radvanyi
Journal: Journal of Clinical Oncology (2009)

3021 Background: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) is a promising therapy for the treatment of metastatic melanoma. Trials at the NCI have shown a 50% response rate. However, outside of the NCI, ACT has been quite limited and little is known about how patient characteristics and prior treatment affect large-scale TIL expansion needed for treatment. Methods: As part of a phase II melanoma ACT clinical trial at M. D. Anderson Cancer Center, we evaluated how clinical characteristics such as age, gender, biopsy site, melanoma type, primary tumor location, and prior treatment of patients (N=134) affected TIL expansion rates. 159 isolated metastatic melanomas (19 patients having &gt;1 tumor harvest) were analyzed for the ability to expand a minimum of 40 million TIL, considered a minimum number for the subsequent rapid expansion protocol (REP) needed for TIL infusion. Effects of these parameters on TIL anti-tumor reactivity and TIL/tumor fragment were also analyzed. Statistical analysis was done by either Fisher's Exact test, Wilcoxon Rank Sum test, or Kruskal-Wallis Test. Results: 54.7% of the samples evaluated generated ≥ 40 million TIL, and 70% of 70 samples tested had anti-tumor reactive TIL. There was a significant relationship between age categories (p=0.0216) and gender (p=0.0164) on TIL expansion success. Younger patients did the best and females did better than males (odds 2.19, p=0.044). The site of the primary melanoma affected success of TIL expansion (p=0.0059), while no effect of tumor biopsy site and histological type was found. Prior chemotherapy (or biochemotherapy) greatly reduced TIL growth (odds 0.32, p=0.010) when compared to no prior therapy. Multivariate linear regression analyses showed that prior chemotherapy decreased TIL/tumor fragment yield by 6.19 million (p=0.0004) while immunotherapy increased it by 3.51 million (p=0.16) compared to no prior therapy. Total TIL yield or TIL/tumor fragment did not correlate with patient overall survival. Conclusions: Parameters such as age, sex, primary melanoma site, and prior therapy significantly affect TIL expansion and should be considered in selecting patients for melanoma ACT. No significant financial relationships to disclose.
Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).
Authors: Esa Jantunen, Ariane Boumendil, Herve Finel, Jian Jian Luan, Peter R. E. Johnson, Alessandro Rambaldi, Andrew Haynes, Michel A. Duchosal, Lothar Kanz, Pierre Biron, Kristina Carlsson, Charles Craddock, Claudius Rudin, Jurgen Finke, Gilles Salles, Peter Dreger, Anna Sureda
Journal: Blood (2012)
Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer
Authors: D. Gschwantler-Kaulich, A. Fink-Retter, T. Bachrich, M. Ledesma, E. Ruecklinger, E. Kubista, C. F. Singer
Journal: Journal of Clinical Oncology (2007)

11098 Background: Neoadjuvant chemotherapy is the treatment of choice for locally-advanced breast cancer and leads to down staging and improved BCT rates. While its efficacy is well established, considerably less is known about the most effective regimen. Methods: We have performed a retrospective analysis of 132 breast cancer patients who had undergone neoadjuvant chemotherapy at our institution. Patients had either received a) anthracyclines (“A”, n=35), b) anthracyclines and taxanes (“AT”, n=55), or c) neither of the two compounds (“NoA/T”, n=42). Clinical response, pathological response and survival were evaluated in each arm. Results: While all three regimen resulted in significant tumor regression, AT was most effective with a mean tumor shrinkage of 39% (ultrasound) and 41% (mammography) (Kruskal-Wallis, p=0.004, and p=0.027). Breast conservation was achieved in 75% by AT, in 49% by A, and in 19% by NoA/T (Kruskal-Wallis, p&lt;0.001). The treatment groups did not differ in respect to pCR (χ 2 -test, p=0.068), although higher cumulative anthracycline doses were predictive of pCR in multivariate analyses (p=0.022). While the mammographic and not the ultrasound-determined tumor diameter determined whether a woman underwent BCT, only an ultrasound-determined size reduction was predictive for DFS and OS (log rank, p=0.0093, and p=0.044, respectively). Other parameters that affected BCT rates were age (p= 0.003), year of diagnosis (p=&lt;0.001), presence of multifocal disease (p= 0.032) and the cumulative anthracycline dose (p= &lt;0.001). Conclusions: While the combination of anthracyclines and taxanes is most effective in achieving clinical remission and BCT, the cumulative anthracycline dose appears most important for achieving pCR. No significant financial relationships to disclose.
Abstract 10748: Quantitative Improvements in Cerebral Blood Flow Detected with Magnetic Resonance Imaging Following Transtemporal Ultrasound and Microbubbles in Pigs with Acute Stroke
Authors: Matthew White, Yan Zhang, Thomas Perkins, Jeffry E Powers, William T Shi, Francois Vignon, Feng Xie, John Lof, Juefei Wu, Jia Liu, Thomas R Porter
Journal: Circulation (2012)

Background. Transtemporal Ultrasound (TTU) and intravenous (IV) microbubbles (MB) have been explored as a method of enhancing the effectiveness of fibrinolytic therapy in acute stroke. However, it ...